<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35256332</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2531-1387</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Hematology, transfusion and cell therapy</Title>
          <ISOAbbreviation>Hematol Transfus Cell Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pediatric Evans Syndrome: A 20-year experience from a tertiary center in Brazil.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">S2531-1379(22)00032-3</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.htct.2022.01.011</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The Evans syndrome (ES) is a rare, often chronic, relapsing and treatment-refractory hematological disorder. We described the clinical features, diagnostic workup, treatment and outcome in patients with ES.</AbstractText>
          <AbstractText Label="METHOD" NlmCategory="METHODS">We performed a retrospective chart review of patients aged &lt; 18 years with ES admitted to a tertiary center in Brazil from 2001 to 2021. The analysis of the data was primarily descriptive, using median, interquartile range and categorical variables presented in absolute frequencies.</AbstractText>
          <AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Twenty patients (12 female, 8 male) were evaluated in this study. The median age at the initial cytopenia was 4.98 years (1.30-12.57). The ES was secondary in nine cases (45%), of which six patients (30%) showed autoimmune disease (AID) or primary immunodeficiencies (PID) and one presented a spontaneous recovery. Steroids and intravenous immunoglobulin were first-line therapy in 19 cases. Twelve patients (63%) required second-line treatments (rituximab, cyclosporine, splenectomy, sirolimus, cyclophosphamide, mycophenolate mofetil, azathioprine and eltrombopag). The median follow-up period was 2.41 years (1.4 -7.52). One patient (5%) died of underlying neuroblastoma, one case (5%) was lost to follow-up and four patients (20%) received a medical discharge. The median age for the 14 remaining cases was 12.6 years. Twelve patients (85.7%) were in complete response (CR) with no therapies. Two patients (14.3%) were in CR with chronic therapy.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">As ES may be a symptom of AID and PID, a thorough rheumatological, immunologic and genetic workup and a careful follow-up are essential. The second-line treatment remains a dilemma. Further prospective studies are needed to address the optimal therapeutic combinations, morbidity and mortality in this disorder.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Blanco</LastName>
            <ForeName>Bruna Paccola</ForeName>
            <Initials>BP</Initials>
            <AffiliationInfo>
              <Affiliation>Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC FMUSP), São Paulo, SP, Brazil. Electronic address: bruna.blanco@hc.fm.usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garanito</LastName>
            <ForeName>Marlene Pereira</ForeName>
            <Initials>MP</Initials>
            <AffiliationInfo>
              <Affiliation>Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC FMUSP), São Paulo, SP, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Brazil</Country>
        <MedlineTA>Hematol Transfus Cell Ther</MedlineTA>
        <NlmUniqueID>101725732</NlmUniqueID>
        <ISSNLinking>2531-1379</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autoimmune hemolytic anemia</Keyword>
        <Keyword MajorTopicYN="N">Autoimmune thrombocytopenia</Keyword>
        <Keyword MajorTopicYN="N">Evans syndrome</Keyword>
        <Keyword MajorTopicYN="N">Pediatrics</Keyword>
      </KeywordList>
      <CoiStatement>Conflicts of interest No authors have any conflict of interest that is directly relevant to the content of this manuscript.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>5</Hour>
          <Minute>36</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35256332</ArticleId>
        <ArticleId IdType="doi">10.1016/j.htct.2022.01.011</ArticleId>
        <ArticleId IdType="pii">S2531-1379(22)00032-3</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
